Brief: Chemomab Reports Independent Drug Monitoring Committee Safety Review Of CM-101 Phase 2 Trial

Chemomab Therapeutics

21/12/2022 12:21

Dec 21 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB REPORTS INDEPENDENT DRUG MONITORING COMMITTEE
SAFETY
REVIEW OF CM-101 PHASE 2 TRIAL IN PRIMARY SCLEROSING CHOLANGITIS
    * CHEMOMAB THERAPEUTICS LTD - CLEAN SAFETY REVIEW SUPPORTS
ADDITION OF HIGHER DOSE COHORT INTO TRIAL
    * CHEMOMAB THERAPEUTICS LTD-DMC HAD NO SAFETY CONCERNS WITH
PROCEEDING WITH ADDING PLANNED 20 MILLIGRAM PER KILOGRAM (MG/KG)
DOSING COHORT TO PSC TRIAL
    * CHEMOMAB THERAPEUTICS LTD - TOP-LINE DATA FROM PHASE 2 PSC
TRIAL
IS EXPECTED IN SECOND HALF OF 2024

Source text for Eikon:  ID:nPnc0DQBca 
Further company coverage:  CMMB.O 
 ((Reuters.Briefs@thomsonreuters.com;))